Carl Byrnes
Stock Analyst at Northland Securities
(0.30)
# 4,495
Out of 5,004 analysts
272
Total ratings
36.9%
Success rate
-3.5%
Average return
Main Sectors:
Stocks Rated by Carl Byrnes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTB Connect Biopharma Holdings | Reiterated: Buy | $7.5 | $1.08 | +594.44% | 3 | Apr 24, 2026 | |
| MDXG MiMedx Group | Reiterated: Buy | $10 → $6 | $4.67 | +28.48% | 27 | Apr 17, 2026 | |
| SPRY ARS Pharmaceuticals | Reiterated: Buy | $25 | $4.08 | +512.75% | 2 | Apr 15, 2026 | |
| RCEL AVITA Medical | Reiterated: Buy | $10 | $11.84 | -15.54% | 2 | Mar 26, 2026 | |
| BLFS BioLife Solutions | Reiterated: Buy | $34 | $38.49 | -11.67% | 37 | Mar 24, 2026 | |
| TLSI TriSalus Life Sciences | Rated: Buy | $13 → $8 | $4.34 | +84.33% | 5 | Mar 23, 2026 | |
| MDAI Spectral AI | Reiterated: Buy | $6 | $1.59 | +277.36% | 12 | Mar 19, 2026 | |
| SNWV SANUWAVE Health | Reiterated: Buy | $55 | $5.04 | +991.27% | 4 | Mar 16, 2026 | |
| BWAY BrainsWay | Reiterated: Buy | $12 → $15 | $13.31 | +12.70% | 14 | Jan 22, 2026 | |
| ALVO Alvotech | Reiterated: Buy | $10 | $5.75 | +73.91% | 18 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 → $4 | $0.2942 | +1,259.62% | 39 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.715 | n/a | 4 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $2 → $1.25 | $13.18 | n/a | 12 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $1.95 | n/a | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $8 → $1 | $0.0001 | n/a | 24 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $2 | $0.0001 | n/a | 24 | Nov 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 → $2 | $30.21 | n/a | 30 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.28 | n/a | 12 | May 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $45 | $62.86 | n/a | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $16.47 | n/a | 1 | Oct 22, 2018 |
Connect Biopharma Holdings
Apr 24, 2026
Reiterated: Buy
Price Target: $7.5
Current: $1.08
Upside: +594.44%
MiMedx Group
Apr 17, 2026
Reiterated: Buy
Price Target: $10 → $6
Current: $4.67
Upside: +28.48%
ARS Pharmaceuticals
Apr 15, 2026
Reiterated: Buy
Price Target: $25
Current: $4.08
Upside: +512.75%
AVITA Medical
Mar 26, 2026
Reiterated: Buy
Price Target: $10
Current: $11.84
Upside: -15.54%
BioLife Solutions
Mar 24, 2026
Reiterated: Buy
Price Target: $34
Current: $38.49
Upside: -11.67%
TriSalus Life Sciences
Mar 23, 2026
Rated: Buy
Price Target: $13 → $8
Current: $4.34
Upside: +84.33%
Spectral AI
Mar 19, 2026
Reiterated: Buy
Price Target: $6
Current: $1.59
Upside: +277.36%
SANUWAVE Health
Mar 16, 2026
Reiterated: Buy
Price Target: $55
Current: $5.04
Upside: +991.27%
BrainsWay
Jan 22, 2026
Reiterated: Buy
Price Target: $12 → $15
Current: $13.31
Upside: +12.70%
Alvotech
Nov 14, 2025
Reiterated: Buy
Price Target: $10
Current: $5.75
Upside: +73.91%
Nov 5, 2025
Reiterated: Buy
Price Target: $9 → $4
Current: $0.2942
Upside: +1,259.62%
Aug 28, 2025
Reiterated: Buy
Price Target: $5
Current: $0.715
Upside: n/a
Jul 19, 2023
Rated: Hold
Price Target: $2 → $1.25
Current: $13.18
Upside: n/a
May 22, 2023
Initiated Coverage: Buy
Price Target: $8
Current: $1.95
Upside: n/a
Jan 6, 2023
Downgraded: Sell
Price Target: $8 → $1
Current: $0.0001
Upside: n/a
Nov 23, 2022
Reiterated: Buy
Price Target: $10 → $2
Current: $0.0001
Upside: n/a
Aug 17, 2022
Reiterated: Buy
Price Target: $4 → $2
Current: $30.21
Upside: n/a
May 14, 2020
Rated: Hold
Price Target: n/a
Current: $2.28
Upside: n/a
Oct 22, 2018
Initiated Coverage: Buy
Price Target: $45
Current: $62.86
Upside: n/a
Oct 22, 2018
Initiated Coverage: Buy
Price Target: n/a
Current: $16.47
Upside: n/a